Last reviewed · How we verify
M-GPE
At a glance
| Generic name | M-GPE |
|---|---|
| Sponsor | Centers for Disease Control and Prevention, China |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS (PHASE1)
- Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M-GPE CI brief — competitive landscape report
- M-GPE updates RSS · CI watch RSS
- Centers for Disease Control and Prevention, China portfolio CI